知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

64 records (took 0.034 seconds)

    RS7 ANTIBODIES
    1.
    发明申请
    RS7 ANTIBODIES 有权
    RS7抗体

    公开(公告)号：US20080131363A1

    公开(公告)日：2008-06-05

    申请号：US11868290

    申请日：2007-10-05

    Applicant: Serengulam Govindan ,  Zhengxing Qu ,  Hans Hansen ,  David Goldenberg

    Inventor： Serengulam Govindan ,  Zhengxing Qu ,  Hans Hansen ,  David Goldenberg

    IPC: A61K39/395 ,  A61K38/20 ,  A61K51/10 ,  A61P35/04

    CPC classification number: C07K16/30 ,  A61K38/164 ,  A61K38/168 ,  A61K38/1816 ,  A61K38/19 ,  A61K38/21 ,  A61K45/06 ,  A61K47/6805 ,  A61K47/6857 ,  A61K51/1054 ,  A61K2039/505 ,  C07K16/28 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/94 ,  A61K2300/00

    Abstract: This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.

    Abstract translation: 本发明涉及单价和多价单特异性结合蛋白和多价多特异性结合蛋白。 这些结合蛋白的一个实施方案具有一个或多个结合位点，其中每个结合位点与靶抗原或靶抗原上的表位结合。 这些结合蛋白的另一个实施方案具有两个或更多个结合位点，其中每个结合位点对靶抗原上的不同表位具有亲和力，或对靶抗原或半抗原具有亲和力。 本发明还涉及可用于在宿主中表达这些功能性结合蛋白的重组载体。 更具体地，本发明涉及称为RS7的肿瘤相关抗原结合蛋白和其它EGP-1结合蛋白。 本发明还涉及人源化，人和嵌合RS7抗原结合蛋白，以及这种结合蛋白在诊断和治疗中的用途。

    Anti-CD19 antibodies
    3.
    发明申请
    Anti-CD19 antibodies 有权
    抗CD19抗体

    公开(公告)号：US20060257398A1

    公开(公告)日：2006-11-16

    申请号：US11445410

    申请日：2006-06-01

    Applicant: Hans Hansen ,  Zhengxing Qu ,  David Goldenberg

    Inventor： Hans Hansen ,  Zhengxing Qu ,  David Goldenberg

    IPC: A61K39/395 ,  C07K16/44 ,  C07K16/28

    CPC classification number: C07K16/2803 ,  A61K2039/507 ,  C07K16/2887 ,  C07K2317/565

    Abstract: The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases.

    Abstract translation: 本发明提供了结合人B细胞标记的人源化，嵌合和人抗CD19抗体，抗-CD19抗体融合蛋白及其片段。 此类抗体，融合蛋白及其片段可用于治疗和诊断各种B细胞病症，包括B细胞恶性肿瘤和自身免疫性疾病。

    RS7 ANTIBODIES
    4.
    发明申请
    RS7 ANTIBODIES 有权
    RS7抗体

    公开(公告)号：US20070212350A1

    公开(公告)日：2007-09-13

    申请号：US11745896

    申请日：2007-05-08

    Applicant: Serengulam Govindan ,  Zhengxing Qu ,  Hans Hansen ,  David Goldenberg

    Inventor： Serengulam Govindan ,  Zhengxing Qu ,  Hans Hansen ,  David Goldenberg

    IPC: A61K39/44 ,  A61K39/395 ,  C07K16/30 ,  C12P21/08

    CPC classification number: A61K45/06 ,  A61K39/39558 ,  A61K51/1045 ,  A61K51/1051 ,  A61K2039/505 ,  C07K16/30 ,  C07K16/3015 ,  C07K2317/21 ,  C07K2317/24

    Abstract: This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.

    Abstract translation: 本发明涉及单价和多价单特异性结合蛋白和多价多特异性结合蛋白。 这些结合蛋白的一个实施方案具有一个或多个结合位点，其中每个结合位点与靶抗原或靶抗原上的表位结合。 这些结合蛋白的另一个实施方案具有两个或更多个结合位点，其中每个结合位点对靶抗原上的不同表位具有亲和力，或对靶抗原或半抗原具有亲和力。 本发明还涉及可用于在宿主中表达这些功能性结合蛋白的重组载体。 更具体地，本发明涉及称为RS7的肿瘤相关抗原结合蛋白和其它EGP-1结合蛋白。 本发明还涉及人源化，人和嵌合RS7抗原结合蛋白，以及这种结合蛋白在诊断和治疗中的用途。

    Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
    6.
    发明申请
    Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer 有权

    公开(公告)号：US20060140936A1

    公开(公告)日：2006-06-29

    申请号：US11296432

    申请日：2005-12-08

    Applicant: David Goldenberg ,  Hans Hansen

    Inventor： David Goldenberg ,  Hans Hansen

    IPC: A61K39/395 ,  C07K16/44

    CPC classification number: A61K39/3955 ,  A61K31/513 ,  A61K38/193 ,  A61K38/2013 ,  A61K38/4866 ,  A61K39/40 ,  A61K45/06 ,  A61K49/0002 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/1203 ,  C07K16/24 ,  C07K16/241 ,  C07K16/248 ,  C07K16/2803 ,  C07K16/2896 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/734

    Abstract: Methods and compositions for immunotherapy of inflammatory and immune-dysregulatory diseases, using multispecific antagonists that target at least two different markers are disclosed. The different targets include (i) proinflammatory effectors of the innate immune system, (ii) coagulation factors, and (iii) targets specifically associated with an inflammatory or immune-dysregulatory disorder, with a pathologic angiogenesis or cancer, or with an infectious disease, wherein the targets included in group (iii) are neither a proinflammatory effector of the immune system nor a coagulation factor. When the multispecific antagonist reacts specifically with a target associated with an inflammatory or immune-dysregulatory disorder, with a pathologic angiogenesis or cancer, or with an infectious disease, it also binds specifically with at least one proinflammatory effector of the immune system or at least one coagulation factor. Thus, the multispecific antagonist contains at least one binding specificity related to the diseased cell or condition being treated and at least one specificity to a component of the immune system, such as a receptor or antigen of B cells, T cells, neutrophils, monocytes and macrophages, and dendritic cells, a modulator of coagulation, or a proinflammatory cytokine. The multispecific antagonists are used in the treatment of various diseases that are generated or exacerbated by, or otherwise involve, proinflammatory effectors of the innate immune system or coagulation factors. Such diseases more particularly include acute and chronic inflammatory disorders, autoimmune diseases, giant cell arteritis, septicemia and septic shock, coagulopathies (including diffuse intravascular coagulation), neuropathies, graft versus host disease, infectious diseases, acute respiratory distress syndrome, granulomatous diseases, transplant rejection, asthma, cachexia, myocardial ischemia, and atherosclerosis. Other diseases also responsive to these therapies include cancers and conditions with pathological angiogenesis.

Patent Agency Ranking